MAYO CLINIC LABORATORIES

1-800-533-1710

RSBV

Rare Subepithelial Autoimmune Blistering Disease Variants, Serum

Patient ID	Patient Name		Birth Date	Sex	Age
321	IMPLEMENTATION, TEST T		1973-05-01	F	52
Order Number	**Client Order Number**	**Ordering Physician**	**Report Notes**		
X100516620	X100516620	TESTING			
Account Information		**Collected**			
C7028846 DLMP Rochester		17 Dec 2025 05:01			

Rare Subepi Blistering Variants, S

p200 Antibodies

MCR

Positive

Abn

Reference Value
Negative

Laminin 332 Antibodies

MCR

Negative

Reference Value
Negative

Collagen VII Antibodies

MCR

Negative

Reference Value
Negative

Other

[1] MCR

See Comment

The rare subepithelial blistering variants (RSBV) test panel uses indirect immunofluorescence on transfected cells to detect antibodies directed against laminin-332, p200, or collagen VII. This panel is intended for in vitro use as an aid in the diagnosis of rare subepithelial autoimmune blistering diseases, including anti-laminin 332 pemphigoid, anti-p200 pemphigoid, epidermolysis bullosa acquisita, and systemic bullous lupus erythematosus.

Testing was negative for detectable antibodies against laminin-332. Rarely, testing is falsely negative if there is a low level of circulating antibody or if antibodies are directed against rare epitopes. Testing was positive for the presence of detectable antibodies against p200. In the appropriate clinical setting, this finding correlates with a diagnosis of p200 pemphigoid. P200 pemphigoid can be associated with psoriasis and may confer a more recalcitrant disease course than conventional pemphigoid. Testing was negative for detectable antibodies against collagen VII. Rarely, testing is falsely negative if there is a low level of circulating antibody or if antibodies are directed against rare epitopes. Recommend correlation with clinical presentation, histopathologic findings from a standard biopsy, direct immunofluorescence from a perilesional biopsy (Mayo test code: CIB), indirect immunofluorescence with IgG and IgG4 (Mayo test code: CIFS), and other testing as clinically indicated. Recent changes to this test, including modifying the reactant to IgG4 from that provided with the testing kit, have improved test sensitivity and specificity. Therefore, clinical decisions should not be based on direct comparison between historical and current test results.

Received: 18 Dec 2025 13:22 **Reported:** 18 Dec 2025 13:26

Laboratory Notes

[1] This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
MCR	Mayo Clinic Laboratories - Rochester Main Campus	200 First Street SW, Rochester, MN 55905	Nikola Baumann Ph.D.	24D0404292